What the Mounjaro questionnaire actually covers — and why it matters

What the clinical evidence tells prescribers before they review your answers

Tirzepatide's questionnaire doesn't exist in a vacuum. It translates the requirements of NICE TA1026 and the medicine's licensed indications into practical screening questions. The SURMOUNT-1 trial (2,539 adults with obesity, published in the New England Journal of Medicine) found that tirzepatide at the highest dose produced around 20–21% average body-weight reduction over 72 weeks. That result came from a tightly characterised trial population with defined inclusion and exclusion criteria. The questionnaire is, in effect, a way for your prescriber to understand how your situation maps onto those criteria.

The licensed indication is equally specific: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, using the medicine alongside a reduced-calorie diet and increased physical activity. The questionnaire asks about BMI precisely because a prescriber cannot issue a valid prescription without confirming it. At the tirzepatide overview page you'll find a fuller account of the medicine's mechanism and evidence base if that context helps you prepare your answers.

Lower BMI thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance, the questionnaire may include an ethnicity question for this reason.

The sections most people find unexpected, and what they're screening for

Most people expect weight and height questions. Fewer expect questions about their gallbladder, pancreas history, or kidney function. These aren't bureaucratic padding. Tirzepatide slows gastric emptying and affects how the gut handles food; conditions such as gastroparesis or a history of pancreatitis are genuine clinical considerations. The NHS medicines page for tirzepatide lists the situations in which the medicine is not suitable or requires extra care.

Questions about current medicines matter too. Tirzepatide can reduce the absorption of oral medicines taken around the same time, oral contraceptives are the clearest example, which is why women using the pill are advised to add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. If the questionnaire asks about your contraception, that's the reason. You can read more about digestive interactions like slowed absorption at the page on how tirzepatide affects digestion.

There will also be questions about mood and mental health. Some patients starting treatment notice changes in how they feel, and prescribers want a baseline. None of this should alarm you, it reflects responsible prescribing, not an attempt to disqualify you.

What a prescriber is looking for when they read your completed questionnaire

Your answers land with a GPhC-registered Independent Prescriber, who reads the full picture before deciding whether to approve, ask a follow-up question, or recommend an alternative. This is not an automated score. A real clinician reads your actual words, the same day, at a GPhC-registered pharmacy you can verify on the GPhC register (premises number 9012878).

The prescriber checks that the eligibility criteria are met, that no contraindications are present, and that the dose-start plan suits your individual circumstances. If there are questions (about a medication you listed, or a condition that needs clarification) they may contact you before reaching a decision. That's a sign of a diligent service, not a problem.

For context on what private treatment typically costs, this page walks through Mounjaro pricing in the UK, including what a legitimate price should cover and what the Eli Lilly list-price changes since September 2025 mean in practice.

What happens after the questionnaire is approved

Once a prescriber approves your treatment, the prescription is issued and passed to our pharmacy the same day. Order before 12pm on a working day and your treatment is dispatched the same day it's approved, arriving the next working day via DPD, in plain unbranded packaging with a tracking notification on your phone. The pen itself is a pre-filled KwikPen: each contains four weekly doses, ready to use.

Treatment starts at 2.5mg. That starting dose is there because the body needs time to settle into the medicine, the early weeks are about tolerability, not yet about maximum effect. Most GI side effects, when they occur, are at their most noticeable in the first few days after a new dose or increase. You can find practical detail on managing indigestion on Mounjaro and on wind and bloating if those are among your concerns. Every repeat order at nume is clinically re-reviewed, there are no automatic renewals.

If you have specific questions about what the questionnaire will ask before you begin, common Mounjaro questions and answers is a practical place to start. Ready to fill in the questionnaire with a prescriber waiting to review it? Check your eligibility.